作者：
Devriese,L.A. [1]
;
Koch,K.M. [2]
;
Mergui-Roelvink,M. [3]
;
Matthys,G.M. [4]
;
Ma,W.W. [5]
;
Robidoux,A. [6]
;
Stephenson,J.J. [7]
;
Chu,Q.S.C. [8]
;
Orford,K.W. [9]
;
Cartee,L. ;
Botbyl,J. ;
Arya,N. ;
Schellens,J.H.M.
作者单位：
Cross Cancer Institute, Edmonton, AB, Canada
[1]
Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands
[2]
Provonix, GlaxoSmithKline, Philadelphia, PA, United States
[3]
Oncology Global Business, Research and Development, GlaxoSmithKline, Philadelphia, PA, United States
[4]
Greenville Hospital System Institute for Translational Oncology Research, Greenville, SC, United
[5]
Centre Hospitalier de l'Université de Montréal-Hotel-Dieu de Montréal, QC, Canada
[6]
Roswell Park Cancer Institute, Buffalo, NY, United States
[7]
Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, Netherlands
[8]
Medicines Discovery and Development, Research and Development, GlaxoSmithKline, Philadelphia, PA
[9]
发布时间
2014-09-12
换一批
